Survival advantage from higher-dose radiation therapy for clinically localized prostate cancer treated on the Radiation Therapy Oncology Group trials.
about
Waiting lists for radiation therapy: a case studyIntensity modulated radiotherapy for high risk prostate cancer based on sentinel node SPECT imaging for target volume definition.Combination of celecoxib with percutaneous radiotherapy in patients with localised prostate cancer - a phase I studyUse of treatment information from a state central cancer registry in prostate cancer research.Helical intensity-modulated radiotherapy of the pelvic lymph nodes with a simultaneous integrated boost to the prostate--first results of the PLATIN 1 trial.Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects.Randomised pilot study of dose escalation using conformal radiotherapy in prostate cancer: long-term follow-upWhole pelvic intensity-modulated radiotherapy for high-risk prostate cancer: a preliminary report.Is there an optimal management for localized prostate cancer?Emerging technologies in prostate cancer radiation therapy: improving the therapeutic window.Exclusive image guided IMRT vs. radical prostatectomy followed by postoperative IMRT for localized prostate cancer: a matched-pair analysis based on risk-groups.Comparison of dose volume histograms for supine and prone position in patients irradiated for prostate cancer-A preliminary study.Long term results of HDR brachytherapy in men older than 75 with localized carcinoma of the prostate.Intraprostatic Fiducials Compared with Bony Anatomy and Skin Marks for Image-Guided Radiation Therapy of Prostate Cancer.Evaluation of techniques for slice sensitivity profile measurement and analysis.Assessment of setup uncertainties for various tumor sites when using daily CBCT for more than 2200 VMAT treatments.Superiority of a soft tissue-based setup using cone-beam computed tomography over a bony structure-based setup in intensity-modulated radiotherapy for prostate cancer.
P2860
Q24798571-BB58B9AC-C183-4264-846C-8879CBCD5A95Q24815261-47E024C9-AF95-4F4A-8CEF-E60BB6DC93D1Q28218423-91DC7D62-BB18-4941-8D7E-8F2C6E60FAB7Q35124541-DFF19153-9B12-42D9-AD0A-9F9339AFC537Q35835108-4C108A00-F2F6-48D1-9023-09CECD34B44EQ36617012-9141D225-1E26-49C9-A682-D8E735E617CAQ37081939-A9C8272E-2E84-48C2-B5FD-E8293B2877BBQ37549491-E0ABB76B-6937-49E1-AE61-9E628B096A8CQ37780107-240BD2C9-559F-4331-8D6C-221A8CF9BB64Q37791392-946B73EA-C569-479F-B9DC-603F6B3BDB77Q41608624-EE05C2B9-6EF7-49F3-A6B1-B97789923504Q42017015-A2BA9634-49E4-4EB6-9698-B8ADC9EE83D1Q42794326-36C44D61-D2D5-47A9-AAAD-1441171A9754Q47145428-CF00E044-FA9C-4F1B-B5D8-892979D03DAFQ51095886-9EEFBF43-5186-4DAC-B5B4-8D423D5AB398Q54986154-77EEB34A-6FB5-4693-934B-F848178AAB65Q55004363-CA7556D6-168E-41CF-8B66-BC9094A1D00B
P2860
Survival advantage from higher-dose radiation therapy for clinically localized prostate cancer treated on the Radiation Therapy Oncology Group trials.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Survival advantage from higher ...... Therapy Oncology Group trials.
@ast
Survival advantage from higher ...... Therapy Oncology Group trials.
@en
type
label
Survival advantage from higher ...... Therapy Oncology Group trials.
@ast
Survival advantage from higher ...... Therapy Oncology Group trials.
@en
prefLabel
Survival advantage from higher ...... Therapy Oncology Group trials.
@ast
Survival advantage from higher ...... Therapy Oncology Group trials.
@en
P2093
P1476
Survival advantage from higher ...... Therapy Oncology Group trials.
@en
P2093
P304
P356
10.1200/JCO.2000.18.14.2740
P407
P577
2000-07-01T00:00:00Z